Previous 10 | Next 10 |
Alcon (SIX: ALC) (NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today that it will report third quarter 2019 results and host a conference call on Wednesday, November 20, at 2:00 p.m. Central European Time / 8:00 a.m. Eastern Time for the qua...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Quick Take Oyster Point Pharma ( OYST ) intends to raise $85 million in an IPO of its common stock, according to an S-1/A registration statement . The company is advancing drug treatments for certain eye conditions. OYST has a potential upside catalyst in mid-2020 and the IPO appears re...
Head-to-head data presentations will show PRECISION1 superior over competitive lenses on critical success factors for new contact lens wearers Clinical findings on AcrySof IQ PanOptix trifocal intraocular lens for the treatment of cataracts to be presented for the first-time ever at a ...
Quick Take Oyster Point Pharma (OYST) has filed to raise gross proceeds of $85 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing treatments for ocular surface diseases. OYST has produced very promising results in Phase 2b trials for its lead ca...
PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs from the AAO IRIS Registry – the largest real-world dataset in ophthalmol...
Alcon (NYSE: ALC ) has priced a private offering of $500M aggregate principal amount of its 2.75% senior notes due 2026, $1B 3.0% senior notes due 2029 and $500M 3.8% senior notes due 2049 (the “Notes”). More news on: Alcon, Inc., Healthcare stocks news, Read more ...
Alcon (SIX/NYSE: ALC) announced that it has priced a private offering of US$500.0 million aggregate principal amount of its 2.75% senior notes due 2026, US$1.0 billion aggregate principal amount of its 3.0% senior notes due 2029 and US$500.0 million aggregate principal amount of its 3.8% sen...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA clinical study said they would choose the same lens again 1 U.S. surgeon tr...
Healthcare research is laying the groundwork for drug technology that has never been seen before. By improving product efficacy and safety, as well as patient convenience and compliance, drugs are becoming more sophisticated with every passing year. Novel drug delivery technologies must overcom...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...